RxDoctor Payments Data

Julia Kuhn, MD

Ophthalmology · Eugene, ORNPI 1275997967

Payments from drug & device makers

$1,499in general payments, 2019–2025

Across 41 payments — averaging $36.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$389
  • Amgen$185
  • Bausch & Lomb Americas Inc.$140
  • Johnson & Johnson Surgical Vision, Inc.$132
  • AbbVie$115
  • Conmed Corporation$99
  • plus $440 from 10 others

What the payments were for

  • Food & beverage$1,499100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,499 in reported general payments places this provider in the 70th percentile of 248 ophthalmology providers in Oregon.

See all ophthalmology providers in Oregon

Medicare billing

Part B allowed, 2024
$680,065
Medicare patients
552
Services billed
4,421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost39$28,333
Latanoprost1,000$17,627
RhopressaNetarsudil Mesylate28$15,886
Prednisolone Acetate373$12,649
Travoprost48$8,156
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat416$6,829
Timolol Maleate347$4,855
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol13$3,868
Brinzolamide26$3,127
SimbrinzaBrinzolamide/Brimonidine Tart12$2,372
Brimonidine Tartrate158$2,188
Ketorolac Tromethamine54$1,582
Fluorometholone15$1,461
Dorzolamide Hcl69$1,282
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha39$511

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$115$28,33339 claims
Aerie Pharmaceuticals, Inc.Rhopressa$17$15,88628 claims
AlconSimbrinza$389$2,37212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 248 ophthalmology providers in Oregon.

Other ophthalmology in Eugene

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →